{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-24-000067","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.435733+00:00","generated_at":"2026-06-03T00:16:23.610873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2","bullets":["PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.","Net loss $81.5M in Q1 2024 vs $81.0M in Q1 2023; cash $714.3M as of March 31, 2024.","Positive Phase 3 ENERGIZE results for mitapivat in non-transfusion-dependent thalassemia announced in January.","ENERGIZE-T topline data expected Q2 2024; FDA filing for mitapivat in thalassemia planned year-end.","Servier's vorasidenib NDA accepted with PDUFA Aug 20, 2024; Agios eligible for $200M milestone and 15% royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-24-000067","json":"https://secwatch.observer/filing/0001439222-24-000067.json","markdown":"https://secwatch.observer/filing/0001439222-24-000067.md","text":"https://secwatch.observer/filing/0001439222-24-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/0001439222-24-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/agio-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:16:23.610873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"445c115425a11a5b82d1639a12b22a496d351fdb","claim":"AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2024 results: revenue $8.2 million.","evidence_excerpt":"RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 2, 2024 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/0001439222-24-000067-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$8.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}